NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
Recruiting now · Early Phase 1
Conditions studied: Liver Cancer, Adult
In brief
This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.
Key facts
- Study ID
- NCT07295262
- Run by
- West China Hospital
- People needed
- 30
- Starts
- 2026-01-01
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2025-12-19
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18-75 years.
- First diagnosis of Hepatocellular Carcinoma (HCC) (non-recurrent).
- Single tumor with diameter ≤ 5 cm.
- Assessed as resectable by more than 2 senior liver surgeons (experience >10 years, >500 hepatectomies).
- No distant metastasis on preoperative chest CT and abdominal contrast-enhanced CT.
- Child-Pugh Class A liver function.
- Patient or legal guardian able to understand the study and sign informed consent.
You may not qualify if…
- Postoperative pathology confirms cholangiocarcinoma, sarcomatoid HCC, combined HCC-ICC, or fibrolamellar carcinoma.
- Presence of portal vein, hepatic vein, or bile duct tumor thrombus.
- History of other malignancies (except cured carcinoma in situ of cervix, basal cell carcinoma, or squamous cell skin carcinoma).
- Evidence of residual lesion, recurrence, or metastasis during preoperative assessment; or postoperative pathology confirming lymph node metastasis or positive margins.
- Moderate to severe ascites requiring therapeutic paracentesis/drainage, or Child-Pugh score > 7 (except for small amount of ascites on imaging without clinical symptoms).
- Uncontrolled or moderate/large amount of pleural effusion or pericardial effusion.
- Severe cardiac, pulmonary, or renal dysfunction.
- Ruptured HCC requiring emergency surgery.
- Patient or family unable to understand the study conditions and objectives.
Where it is running
- West China Hospital — Chengdu, Sichuan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.